GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Beneish M-Score

DexCom (DexCom) Beneish M-Score : -2.41 (As of Apr. 26, 2024)


View and export this data going back to 2005. Start your Free Trial

What is DexCom Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.41 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for DexCom's Beneish M-Score or its related term are showing as below:

DXCM' s Beneish M-Score Range Over the Past 10 Years
Min: -3.75   Med: -2.67   Max: -0.65
Current: -2.41

During the past 13 years, the highest Beneish M-Score of DexCom was -0.65. The lowest was -3.75. And the median was -2.67.


DexCom Beneish M-Score Historical Data

The historical data trend for DexCom's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Beneish M-Score Chart

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 -0.65 -2.45 -2.19 -2.41

DexCom Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -2.52 -2.50 -2.36 -2.41

Competitive Comparison of DexCom's Beneish M-Score

For the Medical Devices subindustry, DexCom's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where DexCom's Beneish M-Score falls into.



DexCom Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of DexCom for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0546+0.528 * 1.0242+0.404 * 0.9586+0.892 * 1.2449+0.115 * 0.8894
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.945+4.679 * -0.032836-0.327 * 1.1136
=-2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $988 Mil.
Revenue was 1034.5 + 975 + 871.3 + 741.5 = $3,622 Mil.
Gross Profit was 656.6 + 623.3 + 546.4 + 462.6 = $2,289 Mil.
Total Current Assets was $4,426 Mil.
Total Assets was $6,265 Mil.
Property, Plant and Equipment(Net PPE) was $1,185 Mil.
Depreciation, Depletion and Amortization(DDA) was $186 Mil.
Selling, General, & Admin. Expense(SGA) was $1,185 Mil.
Total Current Liabilities was $1,556 Mil.
Long-Term Debt & Capital Lease Obligation was $2,573 Mil.
Net Income was 256.3 + 120.7 + 115.9 + 48.6 = $542 Mil.
Non Operating Income was 0.4 + -1.7 + 0 + 0 = $-1 Mil.
Cash Flow from Operations was 133.6 + 269.2 + 190.3 + 155.4 = $749 Mil.
Total Receivables was $752 Mil.
Revenue was 815.2 + 769.6 + 696.2 + 628.8 = $2,910 Mil.
Gross Profit was 541.3 + 494.2 + 449.5 + 398.1 = $1,883 Mil.
Total Current Assets was $3,669 Mil.
Total Assets was $5,392 Mil.
Property, Plant and Equipment(Net PPE) was $1,136 Mil.
Depreciation, Depletion and Amortization(DDA) was $156 Mil.
Selling, General, & Admin. Expense(SGA) was $1,008 Mil.
Total Current Liabilities was $1,839 Mil.
Long-Term Debt & Capital Lease Obligation was $1,352 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(987.5 / 3622.3) / (752.2 / 2909.8)
=0.272617 / 0.258506
=1.0546

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1883.1 / 2909.8) / (2288.9 / 3622.3)
=0.647158 / 0.631891
=1.0242

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4425.9 + 1184.5) / 6264.5) / (1 - (3668.8 + 1135.6) / 5391.7)
=0.104414 / 0.108927
=0.9586

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3622.3 / 2909.8
=1.2449

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(155.9 / (155.9 + 1135.6)) / (186 / (186 + 1184.5))
=0.120712 / 0.135717
=0.8894

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1185.4 / 3622.3) / (1007.7 / 2909.8)
=0.327251 / 0.346312
=0.945

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2572.9 + 1556) / 6264.5) / ((1351.9 + 1839.3) / 5391.7)
=0.659095 / 0.591873
=1.1136

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(541.5 - -1.3 - 748.5) / 6264.5
=-0.032836

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

DexCom has a M-score of -2.41 suggests that the company is unlikely to be a manipulator.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121